Maya Bloomberg
Nurse Practitioner · Miami, FLNPI 1902226566
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Genentech USA, Inc. at 33.6% of the total. Reporting peaked in 2023 at $55,586 and has fallen 67.6% since, to $18,031 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $636.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$68K
- Sanofi$36K
- Novo Nordisk$29K
- Bayer$25K
- AstraZeneca$14K
- Sanofi-aventis U.S. LLC$6K
- plus $25K from 11 others
Across 2 payments — averaging $1988.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$4K
What the payments were for
- Consulting fees$82,51441%
- Speaking & faculty fees$87,59943%
- Travel & lodging$25,40613%
- Food & beverage$6,6253%
- Education$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 92 | $68,077 |
| Sanofi | 61 | $35,609 |
| Novo Nordisk | 42 | $29,203 |
| Bayer | 42 | $24,763 |
| AstraZeneca | 27 | $13,601 |
| Sanofi-aventis U.S. LLC | 1 | $6,160 |
| Global Blood Therapeutics, Inc. | 15 | $6,051 |
| Apellis Pharmaceuticals, Inc. | 2 | $5,325 |
| Pfizer | 8 | $4,892 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $4,517 |
| Novartis | 5 | $1,867 |
| Bioverativ Therapeutics Inc. | 1 | $930 |
| Novo Nordisk Health Care AG | 2 | $880 |
| CSL Behring | 3 | $179 |
| Agios Pharmaceuticals, Inc. | 2 | $128 |
| Genentech, Inc. | 1 | $123 |
| Genetix Biotherapeutics Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$202,323 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxbrytaVoxelotor | 15 | $178,356 |
| ProcritEpoetin Alfa | 18 | $174,181 |
| EliquisApixaban | 20 | $20,861 |
| Deferasirox | 19 | $10,765 |
| Hydroxyurea | 116 | $4,702 |
| Terbutaline Sulfate | 11 | $3,104 |
| Celecoxib | 12 | $466 |
| Gabapentin | 40 | $290 |
| Cyclobenzaprine Hcl | 35 | $165 |
| Pantoprazole Sodium | 15 | $145 |
| Cyproheptadine Hcl | 12 | $133 |
| Naproxen | 19 | $62 |
| Losartan Potassium | 17 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Global Blood Therapeutics, Inc.Oxbryta | $6,051 | $178,35615 claims |
| PfizerEliquis | $4,892 | $20,86120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Miami
- Margarita FernandezMiami$311K
- Haydee KapinMiami$97K
- Terri PollackMiami$59K
- Patricia Novoa-VogtMiami$35K
- Moriane JosephMiami$23K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.